Edition:
United States

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

6.47USD
10:11am EST
Change (% chg)

$0.13 (+2.05%)
Prev Close
$6.34
Open
$6.39
Day's High
$6.50
Day's Low
$6.37
Volume
6,122
Avg. Vol
93,044
52-wk High
$7.24
52-wk Low
$2.26

Chart for

About

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address... (more)

Overall

Beta: 1.37
Market Cap(Mil.): $341.07
Shares Outstanding(Mil.): 53.80
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Chromadex Files For Resale Of Up To 5.6 Mln Shares Of Common Stock By The Selling Stockholders

* CHROMADEX CORP FILES FOR RESALE OF UP TO 5.6 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: [http://bit.ly/2kt48c4] Further company coverage:

Dec 14 2017

BRIEF-ChromaDex Corp qtrly ‍reported net sales of $6.1 million from continuing operations

* Chromadex Corp - qtrly ‍reported net sales of $6.1 million from continuing operations compared to $3.9 million for Q3 of 2016​ Source text: (http://bit.ly/2zpFLpg) Further company coverage:

Nov 09 2017

BRIEF-ChromaDex Q3 loss per share $0.07 from continuing operations

* Q3 sales rose 55 percent to $6.1 million Source text for Eikon: Further company coverage:

Nov 09 2017

BRIEF-Chromadex announces $23 mln private placement of common stock

* Chromadex announces $23 million private placement of common stock

Nov 06 2017

BRIEF-Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 mln

* Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 million - SEC filing Source text: [http://bit.ly/2z2cq3P] Further company coverage:

Oct 31 2017

BRIEF-Chromadex announces top-line results of its second human clinical trial

* Chromadex announces top-line results of its second human clinical trial

Sep 26 2017

BRIEF-ChromaDex Partners with Watsons, for TRU NIAGEN retail launch

* ChromaDex Corp - new partnership with Hong Kong based retailer, A.S. Watson, for launch of U.S. Made TRU NIAGEN) dietary supplement in Asia Source text for Eikon: Further company coverage:

Sep 07 2017

BRIEF-Chromadex's units enter asset purchase agreement with Covance Laboratories Inc​

* Chromadex Corp - ‍on august 21, 2017, co's units entered into an asset purchase agreement with Covance Laboratories Inc​

Aug 23 2017

BRIEF-Chromadex sells its analytical testing business to LabCorp

* Chromadex sells its analytical testing business to LabCorp, to accelerate the expansion of Nicotinamide Riboside and its other patented ingredient technologies

Aug 23 2017

BRIEF-Chromadex announces closing of final tranche of $25 mln strategic investment and appoints two new board members

* Chromadex announces closing of third and final tranche of the $25 million strategic investment led by Mr. Li Ka-shing and appoints two additional board members

Aug 21 2017

Earnings vs. Estimates